SCHEMBL4526115

SCHEMBL4526115

CC(C)(C)OC(=O)NNC(=O)c1cc(F)c(N2CC(NC(=O)OC(C)(C)C)C3(CC3)C2)cc1NC1CC1

nearest known ligand 0.33

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 3/20 0.33
IRAK4 Q9NWZ3 3/20 0.33
TNF P01375 1/20 0.33
KAT8 Q9H7Z6 2/20 0.33
KDM4D Q6B0I6 3/20 0.31
BRD4 O60885 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HTT P42858 1/20 0.31
CTSK P43235 2/20 0.31
KAT6A Q92794 1/20 0.31
KAT5 Q92993 1/20 0.31
F10 P00742 1/20 0.31
PARP1 P09874 1/20 0.31
DRD2 P14416 1/20 0.30
DRD3 P35462 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4526111 1.00 USP30 (0.33) USP30IRAK4TNFKAT8KDM4D
SCHEMBL7559477 0.85 KDM4D (0.31) IRAK4TNFKDM4DBRD4
SCHEMBL7559487 0.85 KDM4D (0.31) IRAK4TNFKDM4DBRD4
SCHEMBL4519973 0.84 USP30 (0.36) USP30IRAK4TNFKAT8KDM4D
SCHEMBL4505737 0.83 TSHR (0.41) USP30ALDH1A1HTTF10
SCHEMBL4524425 0.83 KAT8 (0.34) KAT8KDM4DKAT6AKAT5DRD2
SCHEMBL4524420 0.83 KAT8 (0.34) KAT8KDM4DKAT6AKAT5DRD2
SCHEMBL4515875 0.80 F10 (0.42) USP30KAT8KDM4DCTSKF10
SCHEMBL4515838 0.78 IRAK4 (0.33) IRAK4TNFKAT8ALDH1A1HTT
SCHEMBL4501900 0.78 ROCK2 (0.43) IRAK4KAT8KAT6AKAT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582627-B2 3-Amino-7-[3-(1-aminoethyl)-4-fluoropyrrolidin-1-yl]-1-cyclopropyl-8-methyl-1H-pyrido[4,3-d]pyrimidine-2,4-dione; quinolone antibiotics; bactericides; for antibiotic- resistant bacterial infections, ciprofloxacin- resistant ones; inhibiting wild-type and quinolone- resistant mutants of DNA gryase WARNER-LAMBERT COMPANY (US) 2009-09-01 US disclosed
EP-1255739-B1 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2008-06-11 EP disclosed
US-20060287308-A1 3-Aminoquinazolin-2,4-dione antibacterial agents ZOETIS WLC LLC 2006-12-21 US disclosed
US-7094780-B1 3-aminoquinazolin-2,4-dione antibacterial agents WARNER LAMBERT COMPANY LLC (US) 2006-08-22 US disclosed
US-20060183762-A1 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS ZOETIS WLC LLC 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183762-A1 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS ABL1, NQO2, CBR3 USP30 4162/4885IRAK4 2800/4885TNF 4440/4885
US-20060287308-A1 3-Aminoquinazolin-2,4-dione antibacterial agents ABL1, NQO2, AAAS USP30 4136/4885IRAK4 2776/4885TNF 4397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.